{"id":27255,"date":"2014-08-01T12:27:18","date_gmt":"2014-08-01T12:27:18","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=27255"},"modified":"2014-08-19T15:44:51","modified_gmt":"2014-08-19T15:44:51","slug":"short-term-safety-of-atazanavirritonavir-based-second-line-treatment-in-zambia","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/27255","title":{"rendered":"Short-term safety of atazanavir\/ritonavir-based second line treatment in Zambia"},"content":{"rendered":"

\"Globe\"<\/a>Polly Clayden, HIV i-Base<\/strong><\/p>\n

Atazanavir\/ritonavir (ATV\/r) was well tolerated in a Zambian cohort according to data presented at 8th INTEREST.<\/strong><\/p>\n

The Zambian HIV treatment programme introduced ATV\/r as an alternative second-line protease inhibitor to lopinavir\/ritonavir (LPV\/r) in 2013. There are currently limited data describing the use of ATV\/r-based regimens in sub-Saharan Africa.<\/p>\n

Mpande Mukumbwa-Mwenechanya from the Centre for Infectious Disease Research in Zambia showed findings from an evaluation of adults who started ATV\/r-based second-line ART at the University Teaching Hospital in Lusaka between November 2012 and February 2014. The investigators used multivariable logistic regression to assess potential risk factors – age, sex and transaminases – for hyperbilirubinaemia.<\/p>\n

The investigators found, of 103 patients receiving an ATV\/r-based regimen with evaluable data, 44 (43%) had no prior exposure to LPV\/r and 59 (57%) were switched to ATV\/r because of suspected LPV\/r-related side effects (gastrointestinal intolerance and hyperlipidaemia).<\/p>\n

The participants were similar in both treatment groups: median of 42.5 years old and had been taking ATV\/r for a median of 7.5 months (IQR 6-11) and just over a third were men.<\/p>\n

The majority reported no side effects (n=90, 87%). The participants most commonly reported yellow eyes (n= 8, 8%). Hyperbilirubinaemia was the most common adverse event overall (n= 19, 18%). The range was 27.5 to 141 umol\/L and it was not associated with age, sex or elevated transaminases: HR 1.02 (95% CI 0.98-1.06), HR 0.82 (95% C: 0.31-2.14), HR 0.92 (95% CI 0.41-1.87) respectively. Only one participant stopped his ATV\/r-based regimen due to severe abdominal pain.<\/p>\n

Comment<\/h3>\n

Although a small and short-term study these data are reassuring. The LPV\/r monopoly is quite entrenched for second-line in low-income settings, despite generic co-formulated ATV\/r being available and generally considered to be a more tolerable protease inhibitor.<\/strong><\/p>\n

Reference:<\/p>\n

Mwenechanya MM et al. Short-term safety profile of atazanavir\/ritonavir-based second-line therapy among HIV-infected adults in Zambia. 8th International Workshop on HIV Treatment, Pathogenesis and Prevention Research in Resource-Poor Settings (INTEREST). 5-6 May 2014. Lusaka, Zambia. Oral abstract: O_04.
\nhttp:\/\/regist2.virology-education.com\/2014\/8INTEREST\/40_Mpande.pdf<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Polly Clayden, HIV i-Base Atazanavir\/ritonavir (ATV\/r) was well tolerated in a Zambian cohort according to data presented at 8th INTEREST. The Zambian HIV treatment programme introduced ATV\/r as an alternative second-line protease inhibitor to lopinavir\/ritonavir (LPV\/r) in 2013. There are …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[193],"class_list":["post-27255","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-8th-interest"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/27255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=27255"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/27255\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=27255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=27255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=27255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}